Posts tagged special protocol assessment agreement
In conversation with David Luci

As president, CEO and a co-founder of Dipexium Pharmaceuticals (NASDAQ:DPRX), David Luci, and executive chairman and co-founder, Robert DeLuccia, have spearheaded development of Locilex, which could be the first FDA-approved antibiotic specifically to treat mild infections of diabetic foot ulcers (DFI). The two men were instrumental in acquiring the worldwide writes to Locilex five years ago and leading its reformulation and clinical progress. They are experienced pharmaceutical executives with a proven track record of success in drug development and partnering with, and selling to, Big Pharma. In this interview with, Mr. Luci discusses the clinical status of Locilex in the U.S., plans for regulatory approval in Europe and commercialization.

Read More